IVP
IRWD icon

Intrinsic Value Partners’s Ironwood Pharmaceuticals IRWD Stock Holding History

Intrinsic Value Partners’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-45,435
Closed -$296K – 64
2024
Q2 		$296K Sell
45,435
-2,310
-5% -$16.3K 0.31% 53
2024
Q1 		$416K Sell
47,745
-1,710
-3% -$20.8K 0.44% 45
2023
Q4 		$566K Sell
49,455
-900
-2% -$8.9K 0.66% 32
2023
Q3 		$485K Sell
50,355
-50
-0.1% -$490 0.62% 35
2023
Q2 		$536K Sell
50,405
-1,200
-2% -$12.9K 0.68% 37
2023
Q1 		$543K Sell
51,605
-300
-0.6% -$3.36K 0.73% 34
2022
Q4 		$643K Sell
51,905
-1,900
-4% -$21.6K 0.88% 29
2022
Q3 		$557K Sell
53,805
-300
-0.6% -$3.4K 0.77% 32
2022
Q2 		$624K Sell
54,105
-374
-0.7% -$4.41K 0.8% 30
2022
Q1 		$685K Sell
54,479
-578
-1% -$6.63K 0.73% 31
2021
Q4 		$642K Buy
+55,057
New +$675K 0.68% 29

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Intrinsic Value Partners's IRWD Position: Q3 2024 in Review

Intrinsic Value Partners sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2024, closing a stake of 45,435 shares — an estimated $296K sold.

Intrinsic Value Partners first reported a position in IRWD in Q4 2021 and held it in 11 quarters. The position peaked at $685K in Q1 2022. 221 funds tracked by Wall St. Rank hold IRWD as of Q3 2024.

  • Intrinsic Value Partners reported no remaining Ironwood Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Intrinsic Value Partners sold 45,435 Ironwood Pharmaceuticals shares in Q3 2024, an estimated $296K.
  • Intrinsic Value Partners first reported a position in Ironwood Pharmaceuticals in Q4 2021 and held it in 11 quarters.
  • Intrinsic Value Partners's Ironwood Pharmaceuticals position peaked at $685K in Q1 2022.
  • 221 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2024.

Based on Intrinsic Value Partners's 13F filing for Q3 2024, filed 4 Nov 2024.